Innovent Advances Late-Stage Trial for Potential First-in-Class Cancer Drug

The trial, which aims to recruit 550 participants, marks a significant push to address "immune-cold" tumors that typically remain unresponsive to traditional checkpoint inhibitors. IBI363, developed in partnership with Takeda, acts as a PD-1/IL-2α-biased molecule. By simultaneously blocking PD-1 and stimulating tumor-specific CD8+ T cells, the therapy aims to reshape the tumor microenvironment to improve survival outcomes in patients with microsatellite stable colorectal cancer.

Early data from a Phase 1 study presented at the 2025 ASCO meeting provided the basis for the current registrational effort. In that cohort, the combination therapy showed a confirmed objective response rate of 15.1% and a disease control rate of 61.6%. Following these results, Chinese regulators granted the drug Breakthrough Therapy Designation in May 2026. This trial is one of several ongoing global studies for IBI363, which is also being tested in melanoma and non-small cell lung cancer, reflecting its broad potential as a next-generation immunotherapy.